Leukemia

Selinexor in combination with standard induction and consolidation therapy appears highly active in older patients with de novo acute myeloid leukemia. Read More ›

CLL1-CD33 Compound CAR (cCAR) T-Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia

Leukemia

2020 Year in Review - AML

This first-in-human study indicates that CLL1-CD33 cCAR has favorable efficacy and manageable toxicity in patients with R/R AML. Read More ›

Noteworthy Numbers: Acute Lymphocytic Leukemia

Leukemia, Noteworthy Numbers

TON - February 2020, Vol 13, No 1

Leukemia is the most frequently diagnosed cancer in children and adolescents, representing approximately 1 of 3 cancers in these populations of patients. Of the 4 main types of leukemia (acute myeloid leukemia, acute lymphocytic leukemia [ALL], chronic myeloid leukemia, and chronic lymphocytic leukemia), ALL is the most common type found in children and adolescents. The following provides key statistics and other helpful information regarding ALL.

Fixed-Duration Venetoclax plus Obinutuzumab New Standard of Care for Front-Line Treatment of Patients with CLL and Comorbidities

By Phoebe Starr

Leukemia

TON - October 2019, Vol 12, No 5

In the phase 3 CLL14 clinical trial, fixed-duration venetoclax plus obinutuzumab was superior to chlorambucil plus obinutuzumab as front-line therapy in older patients with chronic lymphocytic leukemia (CLL) and comorbidities. The fixed-duration regimen significantly improved progression-free survival (PFS), complete response (CR) rate, and minimal residual disease (MRD) negativity versus chlorambucil plus obinutuzumab, and was superior in patients with poor prognostic factors, such as unmutated IGHV and TP53 alterations. Read More ›

$Gilteritinib a New Standard of Care for Relapsed or Refractory AML with FLT3 Mutation$

Gilteritinib a New Standard of Care for Relapsed or Refractory AML with FLT3 Mutation

By Phoebe Starr

Leukemia

TON - June 2019, Vol 12, No 3

Atlanta, GA—Treatment with gilteritinib (Xospata) significantly improved overall survival (OS) with less toxicity compared with chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) and FLT3 mutation, according to the final results of ADMIRAL, a phase 3 clinical trial presented at the 2019 American Association for Cancer Research meeting. Read More ›

Online Only

Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy

By Loretta Fala, Medical Writer

FDA Updates, Leukemia

2019 Fourth Annual Oncology Guide to New FDA Approvals

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow that is characterized by the production of abnormal myeloblasts, red blood cells, or platelets. AML originates in the bone marrow, but it often spreads into the blood and to other parts of the body, including the lymph nodes, liver, spleen, and central nervous system. Read More ›

Lumoxiti (Moxetumomab Pasudotox-tdfk) First CD22-Directed Cytotoxin FDA Approved for Relapsed or Refractory Hairy-Cell Leukemia

By Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates, Leukemia

2019 Fourth Annual Oncology Guide to New FDA Approvals

Hairy-cell leukemia (HCL) is a rare and indolent hematologic cancer. HCL, which is 4 to 5 times more frequent in men than in women, accounts for 2% of all leukemias. Approximately 1000 new cases of HCL are diagnosed in the United States annually. Read More ›

Tibsovo (Ivosidenib) First Targeted Therapy Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation

By Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Updates, FDA Updates, Leukemia

2019 Fourth Annual Oncology Guide to New FDA Approvals

Acute myeloid leukemia (AML) is a rare but deadly cancer. In 2018, approximately 19,500 new cases of AML were estimated to be diagnosed in the United States and more than 10,600 people to die from the disease. Clinical trials data show that up to 70% of adults with AML have disease that completely responds to initial treatment with cytotoxic chemotherapy. However, the 3-year survival rate for patients with AML remains poor, at approximately 25%. Read More ›

Leukemia

View the Latest Issue of TON

Subscribe Today!

I'd like to receive:

Leukemia

Page 4 of 6

View the Latest Issue of TON

Subscribe Today!

I'd like to receive: